CSI is a medical device company that develops and commercializes solutions for treating peripheral and coronary vascular diseases.Read more
Chairman & CEO
Scott R. Ward
CSI's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 3.1B. Over the last four quarters, CSI's revenue has decreased by 11.1%. Specifically, in Q1 2022's revenue was $56.2M; in Q4 2021, it was $59.1M; in Q3 2021, it was $58.4M; in Q1 2021, CSI's revenue was $63.3M.